BRAINSTORM CELL (BCLI) director receives 225,000 stock options at $0.70 strike

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

HARTOUNIAN HARTOUN reported acquisition or exercise transactions in this Form 4 filing.

BRAINSTORM CELL THERAPEUTICS INC. director Hartoun Hartoun received a grant of stock options to buy 225,000 shares of common stock at $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan and expire on February 26, 2036.

The award vests over a short period: 50% of the options vest on the grant date and the remaining 50% vest on the six‑month anniversary, as long as Hartoun remains employed through each vesting date. After this grant, he holds 225,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HARTOUNIAN HARTOUN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	225,000	$0.70	$158K

Holdings After Transaction: Stock Option (Right to Buy) — 225,000 shares (Direct, null)

Footnotes (1)

Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Key Figures

Options granted: 225,000 options Exercise price: $0.70 per share Underlying shares: 225,000 shares +4 more

7 metrics

Options granted 225,000 options Stock Option (Right to Buy) grant on February 26, 2026

Exercise price $0.70 per share Conversion or exercise price for granted options

Underlying shares 225,000 shares Common Stock underlying the stock options

Post-transaction options held 225,000 options Total derivative securities following the grant

Option expiration date February 26, 2036 Expiration of Stock Option (Right to Buy)

Initial vesting 50% on grant date Vesting condition from footnote F2

Remaining vesting 50% at six-month anniversary Subject to continued employment with issuer

Key Terms

Stock Option (Right to Buy), 2014 Stock Incentive Plan, vesting, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2014 Stock Incentive Plan financial

"granted under the Issuer's 2014 Stock Incentive Plan"

vesting financial

"The Stock Options shall vest as to (i) 50% of the award"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

05/20/2026 - 06:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HARTOUNIAN HARTOUN

(Last)

(First)

(Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)⁽¹⁾	$0.7	02/26/2026		A		225,000		⁽²⁾	02/26/2036	Common Stock	225,000	$0.7⁽¹⁾	225,000	D

Explanation of Responses:

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.

2. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Hartoun Hartounian	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BCLI director Hartoun Hartoun report on this Form 4?

Hartoun Hartoun reported receiving a grant of stock options for 225,000 shares of BCLI common stock. The options are a compensation-related award, giving him the right to buy shares at a fixed exercise price of $0.70 per share.

What is the exercise price and expiration date of the BCLI options granted to Hartoun Hartoun?

The granted stock options have an exercise price of $0.70 per share and expire on February 26, 2036. This means he can choose to purchase BCLI common shares at $0.70 any time before that expiration date, subject to vesting.

How do the BCLI stock options granted to Hartoun Hartoun vest?

The stock options vest in two equal tranches: 50% of the award vests on the grant date and the remaining 50% vests six months later. Vesting is conditioned on Hartoun remaining employed by BRAINSTORM CELL THERAPEUTICS INC. through each applicable vesting date.

How many BCLI options does Hartoun Hartoun hold after this Form 4 transaction?

After this grant, Hartoun Hartoun holds 225,000 stock options directly. Each option corresponds to one share of BCLI common stock, so the position represents rights over 225,000 underlying shares if exercised according to the plan’s terms.

Is the BCLI Form 4 transaction an open-market buy or sell of common stock?

No, this Form 4 reports a grant of stock options, not an open-market trade in common stock. The transaction is coded as a grant or award (code A), reflecting compensation rather than a market purchase or sale of existing BCLI shares.